Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| B670201731744 | Other Identifier | Registration of studies Belgium |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| BioComp Industries bv | UNKNOWN |
Not provided
Not provided
Not provided
Not provided
Not provided
Patients with craniofacial defects caused by oncologic resection, traumatic events or congenital etiologies suffer from esthetic, functional and psychological problems. Auricular, nasal and orbital defects can be reconstructed with implant retained extra-oral prosthesis. The goal of this study is to evaluate implant survival in temporal, maxillary and orbital bone, and peri-implant tissue reactions using a new implant system developed by BioComp Industries.
Protocol:
Planning The ideal size and location of the implants is based on pre-operative CT or CBCT scan followed by analysis using romexis planning software.
In normal circumstances, without bone limitations, the number and location of the implants will be planned as mentioned below:
If for some reason there is insufficient bone in the above mentioned areas, the position of the implants will be minimally adjusted in order to secure good osseointegration. Neuronavigation will be used for cases with limited bone volume.
Flap design During surgery the first step is the creation of a skin flap or resection of a tumor, exposing the area for implantation.
Implantation The implantation protocol as described by BioComp Industries will be used. Each drilling procedure is executed by 1800-2000rpm with water cooling.
For auricular, orbital and nasal defects with sufficient bone volume (>=3mm) and good bone quality, a percutaneous healing abutment with torque 20-25 ncm will be placed immediately after insertion of the implant (=one-stage protocol). Soft tissues in an area of 15-20mm surrounding the implant will be reduced to 1mm thickness.
In all other circumstances, the implant will be protected by means of a cover screw and reburied under the skin for a 3 month osseointegration period (=two-stage protocol). After 3 months the implants are exposed, percutaneous healing abutments placed and the surrounding soft tissues reduced to 1mm thickness.
In the case of large resections where no viable skin is left, a split thickness skin graft from the upper thigh will be used.
Finally, a healing cap surrounding the healing abutments is placed to ensure strong bone-skin contact around the implant. This healing cap will be fixated by a fixation screw, torqued at 15 Ncm.
Clinical measurements:
The stability of the implants will be measured at the time of abutment placement, 1 or 2 weeks, 1 month, 3 months, 6 months and yearly until the end of the study by resonance frequency analysis (RFA), using the Osstell idx system.
At the same time periods the peri-abutment tissue will be evaluated according to the Holgers criteria.
Once all implants have reached a stability measurement of 50 ISQ, the patient will be sent to the anaplastologist for prosthesis treatment.
In case one or more of the implants fail during the study period, the implant will be removed and replaced by a new implant. The protocol will restart for the newly placed implant.
Radiological measurements:
The bone level around the implants will be measured at 1 or 2 weeks after implant placement and 1 year after implant placement. Radiological imaging will be performed using a cone beam computed tomography device (planmeca promax 3d max) or CT scan, dependent on primary imaging in order to allow comparison between both images.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Study group | Experimental | Everybody enrolled in the study will receive BioComp Industries cranio-maxillo-facial (CMF) screw implants |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Implantation of BioComp Industries cranio-maxillo-facial (CMF) screw implants | Device | Placement of BioComp Industries extraoral screw implants with diameters 3.4mm or 4mm and lengths 3.4mm or 4mm in temporal, nasal or orbital bone |
| Measure | Description | Time Frame |
|---|---|---|
| Implant survival | Implant stability measurement with Osstell IDX system | 1 year |
| Peri-implant tissue reaction | Measurement of peri-implant pockets and soft tissue according to Holgers criteria | 1 year |
| Measure | Description | Time Frame |
|---|---|---|
| Bone level | Bone level measurement using CBCT or CT scan | 1-2 weeks post-operative, 1 year |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Hubert Vermeersch, MD, PhD | Em. Professor | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University Hospital | Ghent | Oost-Vlaanderen | 9000 | Belgium |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|